Elsevier

Cellular Signalling

Volume 41, January 2018, Pages 89-96
Cellular Signalling

Review
Niclosamide: Beyond an antihelminthic drug

https://doi.org/10.1016/j.cellsig.2017.04.001Get rights and content

Highlights

  • Niclosamide is an oral antihelminthic drug used to treat parasitic infections.

  • Niclosamide is a multifunctional drug inhibiting multiple signaling pathways and biological processes.

  • Niclosamide has biological activities potentially against systemic diseases.

Abstract

Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of people worldwide. However recent studies have indicated that niclosamide may have broad clinical applications for the treatment of diseases other than those caused by parasites. These diseases and symptoms may include cancer, bacterial and viral infection, metabolic diseases such as Type II diabetes, NASH and NAFLD, artery constriction, endometriosis, neuropathic pain, rheumatoid arthritis, sclerodermatous graft-versus-host disease, and systemic sclerosis. Among the underlying mechanisms associated with the drug actions of niclosamide are uncoupling of oxidative phosphorylation, and modulation of Wnt/β-catenin, mTORC1, STAT3, NF-κB and Notch signaling pathways. Here we provide a brief overview of the biological activities of niclosamide, its potential clinical applications, and its challenges for use as a new therapy for systemic diseases.

Keywords

Niclosamide
Cancer
Bacterial and viral infection
Lupus
Metabolic diseases
Type II diabetes
NASH
NAFLD
Neuropathic pain
Rheumatoid arthritis
Sclerodermatous graft-versus-host disease
Systemic sclerosis

Cited by (0)

View Abstract